Can We Define the Risk of Lymph Node Metastasis in Early-Stage Cervical Cancer Patients? A Large-Scale, Retrospective...

Area of Science:

• Gynecologic Oncology
• Surgical Pathology
• Cancer Staging

Background:

• Sentinel lymph node (SLN) biopsy is crucial for staging early-stage cervical cancer (ECC).
• Current guidelines recommend unilateral lymph node dissection (LND) alongside SLN mapping.
• Previous research identified ECC patients without lymph node metastasis (LNM).

Purpose of the Study:

• To precisely define the risk of LNM in ECC patients.
• To tailor surgical interventions for ECC based on individual LNM risk.
• To identify candidates for whom SLN biopsy might be safely omitted.

Main Methods:

• Retrospective analysis of clinical and pathological data from 463 ECC patients across eight Italian institutions.
• Statistical analysis using Chi-square or Fisher's exact tests and logistic regression.
• Calculation of LNM probability based on logistic regression outcomes.

Main Results:

• 161 patients (34.8%) were classified as Very Low Risk with no detected LNM.
• Among the remaining 302 patients, the precise risk of LNM was calculated.
• A subset of 31 patients (10.3%) had a calculated LNM risk of less than 1%.

Conclusions:

• Precise LNM risk stratification can optimize surgical management in ECC.
• This approach may allow for the avoidance of lymph node procedures, including SLN biopsy, in selected patients.
• Tailoring surgery based on LNM risk improves patient selection and potentially reduces surgical burden.